MedTrace Logo

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

NCT03927157 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2025-07-01

Study results available
· View outcomes & findings →

Summary

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma

Conditions

Interventions

BIOLOGICAL

Experimental: Tezepelumab

Tezepelumab subcutaneous injection

OTHER

Placebo

Placebo subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Nanshan Zhong, Bachelor · Guangzhou institute of Respiratory Disease, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-14
Primary Completion
2024-05-24
Completion
2024-08-13
FDA Drug
Yes

Countries

  • China
  • Philippines
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03927157 on ClinicalTrials.gov